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Abstract
The optimal treatment strategy of newly diagnosed glioma is strongly influenced by tu-
mour malignancy. Manual non-invasive grading based on MRI is not always accurate and
biopsies to verify diagnosis negatively impact overall survival. In this paper, we propose a
fully automatic 3D computer-aided diagnosis (CAD) system to non-invasively differentiate
high-grade glioblastoma from lower-grade glioma. The approach consists of an automatic
segmentation step to extract the tumour ROI followed by classification using a 3D convo-
lutional neural network. Segmentation was performed using a 3D U-Net achieving a dice
score of 88.53% which matches top performing algorithms in the BraTS 2018 challenge.
The classification network was trained and evaluated on a large heterogeneous dataset of
549 patients reaching an accuracy of 91%. Additionally, the CAD system was evaluated
on data from the Ghent University Hospital and achieved an accuracy of 92% which shows
that the algorithm is robust to data from different centres.
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1. Introduction
Tumour malignancy has a strong influence on therapy planning and prognosis of newly
diagnosed glioma. Whereas a watch-and-wait policy can be opted in case of low-grade
glioma, maximum safe resection combined with appropriate chemotherapy and radiotherapy
is recommended by EANO for high-grade glioma (Weller et al., 2017). Differentiation
between low- and high-grade glioma is usually based on MRI with gadolinium-based contrast
agents. The presence of contrast enhancement and necrosis are indicative of higher tumour
malignancy, however 40-45% of non-enhancing lesions are subsequently found to be highly
malignant (Jansen et al., 2012). This results in reduced accuracy of non-invasive tumour
grading (sensitivities ranging between 55% and 83%). Biopsies to confirm histopathological
diagnosis negatively impact overall survival (Wijnenga et al., 2017) and hence accurate non-
invasive grading is preferred. Most CAD methods for glioma grading reported today are
not fully automatic and often trained and evaluated on a small dataset from one clinical
centre (Yang et al., 2018).
In this study we designed a fully automatic computer-aided diagnosis system to non-
invasively discriminate high-grade glioblastoma (GBM) from lower-grade glioma (WHO
grade II and III) using convolutional neural networks that are trained and evaluated on a
large multi-centre dataset.
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2. Methods
2.1. Data
The data used in the work originates from both public datasets and data that was retro-
spectively acquired from the Ghent University Hospital, with permission of the local ethics
committee (Belgian registration number B670201838395 2018/1500). The included pub-
lic databases are the BraTS 2018 dataset (Menze et al., 2015; Bakas et al., 2017a) and
the TCGA-GBM (Scarpace et al., 2016), TCGA-LGG (Pedano et al., 2016) and LGG-
1p19qDeletion (Erickson et al., 2017) collections on The Cancer Imaging Archive (Clark
et al., 2013). Inclusion criteria were: a histologically proven glioma of WHO grade II, III
or IV and the availability of a preoperative T1ce MRI together with a FLAIR and/or T2
sequence of sufficient quality. In total 549 patients were acquired from the public databases
and 112 patients from the University Hospital resulting in data from 660 patients. All MRI
were co-registered, interpolated to 1 mm3 voxel sizes, bias corrected and skull-stripped us-
ing SPM12. Each modality of every patient is independently normalised by subtracting the
mean and dividing by the standard deviation.
2.2. Segmentation
The first part of the Grading system consists of segmenting the whole tumour volume. As
U-Nets have shown state-of-the-art performance for brain tumour segmentation in recent
BraTS challenges, we implemented a 3D U-Net similar to the architecture proposed in
Isensee et al. (2018) with 25 features at the highest resolution, instance normalisation and
leaky ReLUs. The network was trained on random patches of size 128x128x128, batch size of
two, ADAM optimisation (lrinit = 1·10−4), soft dice loss and L2 weight decay of 10−5. From
the 285 patients in the BraTS 2018 training data, 60 were used for validation. The network
was finally evaluated on 76 patients from the TCGA-GBM and TCGA-LGG collections
that were included in the BraTS 2018 test data (Bakas et al., 2017b). For patients from
TCIA and the University Hospital, not all four MRI sequences (T1, T1ce, T2 and FLAIR)
are always available. Therefore, during training, the T1 and the T2 or FLAIR channels are
randomly set to zero to increase robustness to missing modalities.
2.3. Grading
After segmentation, the glioma is classified as a glioblastoma or a lower-grade glioma (WHO
grade II or III). To this end, a tumour region of interest (ROI) is extracted from the T1ce
MRI, resized to a size of 112x112x112 and subsequently fed into the classification network.
The used network architecture (see Figure 1) consists of one convolutional layer with a kernel
size of 7 followed by 4 residual blocks. Every convolutional layer is succeeded with instance
normalisation and a ReLU layer. The network is trained using SGD (lrinit = 1 · 10−3,
momentum = 0.9), L2 weight decay of 10−5 and a batch size of 8. To prevent overfitting,
data augmentations like flipping, rotations, and padding were applied on the fly during
training. Four hundred patients were used for training (200 GBM and 200 LGG cases), 69
for validation (35 GBM, 34 LGG) and 80 TCIA patients for final evaluation (34 GBM, 46
LGG). We made sure that test patients were not used in the training set of the segmentation
network in order to evaluate the system on data that both parts have never seen before.
2
Automatic Glioma Grading based on Pre-Therapy MRI using 3D CNNs
The University Hospital data (63GBM, 49 LGG) was used to test the performance on a final
independent dataset. Both the segmentation and classification networks were implemented
in PyTorch and trained on an 11GB NVIDIA GTX 1080 Ti GPU.
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Figure 1: Architecture used to classify a tumour ROI as GBM or LGG. Every convolutional
layer is succeeded with instance normalisation and a ReLU activation.
3. Results and Discussion
The obtained whole tumour dice scores on the 76 BraTS 2018 test patients were 88.53%,
86.38% and 84.62% when providing all four modalities, only T1ce and FLAIR and only
T1ce and T2 sequences as input respectively. These scores match the performance of state-
of-the-art algorithms in the most recent BraTS 2018 challenge (Myronenko, 2018). Small
variations between manual and predicted segmentations won’t have a strong influence on
the tumour ROI, making the obtained performance sufficient for the current task.
The area under the ROC curve (AUC), matthews correlation coefficient (MCC), ac-
curacy, sensitivity (percentage of GBM cases that are correctly classified as such) and
specificity scores on the TCIA test set and University Hospital data are shown in Table 1.
These results indicate that, to the best of the authors’ knowledge, state-of-the-art grading
performance is achieved using a system that is trained on a large heterogeneous dataset and
is fully automatic. Moreover, the strong performance on independent data from the Ghent
University Hospital shows that it is robust to variations in imaging protocols and data from
different clinical centres.
Table 1: Results of the binary glioma grading system on both data from TCIA and the
Ghent University Hospital
Dataset AUC MCC Acc. Sens. Spec.
TCIA Test Data 96.29 82.19 91.25 91.18 91.30
Ghent Univeristy Hospital Data 93.39 83.91 91.96 90.48 93.88
4. Conclusion
In this paper we presented a fully automatic 3D approach to classify glioma as a high grade
glioblastoma or lower-grade glioma based on pre-therapy structural MRI which has impor-
tant value for optimal therapy planning and prognosis. The two-step procedure consisting
of segmentation using a 3D U-Net and classification with a 3D residual network achieved
state-of-the-art results on a large heterogeneous dataset and generalises well to data from
different centres.
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